This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gordon F. Schwartz, MD; Ronald I. Cantor, MD; William A. Biermann, MD

Arch Surg. 1987;122(12):1430-1434.

Abstract
• One hundred women with American Joint Committee (AJC) stage III (T2, N2; T3, N0/1/2; T4, N0/1/2) carcinoma of the breast were treated with combination chemotherapy following biopsy to confirm the diagnosis and determine hormone receptor status before any other treatment of the local disease (so-called neoadjuvant chemotherapy). Response was assessed after three cycles of treatment, and responders were treated until the tumor and/or axillary nodes failed to show further regression. Definitive surgery was then performed, usually radical mastectomy. Chemotherapy was resumed following surgery for a total of 12 cycles. Ninety patients are assessable, and 70% have responded to chemotherapy. Outcomes of both responders and nonresponders were analyzed. Radical mastectomy without postoperative radiotherapy seems to be the preferable surgical treatment for the responders. Median follow-up of the assessable patients was 27 months; projected five-year disease-free survival of the responders is greater than 65%, and projected overall five-year survival of this group is greater than 85%. Because the follow-up of these patients suggests a marked improvement in outcome compared with similar patients treated traditionally with mastectomy or radiotherapy followed by adjuvant chemotherapy, we advocate more widespread use of combination chemotherapy before definitive treatment for stage III carcinomas of the breast.

(Arch Surg 1987;122:1430-1434).

Author Affiliations
From the Departments of Surgery (Dr Schwartz) and Medicine (Medical Oncology) (Drs Cantor and Biermann), Jefferson Medical College, Philadelphia.

Footnotes
Accepted for publication July 20, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 26, 1987.

Reprint requests to 1015 Chestnut St, Suite 510, Philadelphia, PA 19107 (Dr Schwartz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
Evans et al.
JCO 2005;23:2988-2995.
ABSTRACT | FULL TEXT  

Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study
Delille et al.
Radiology 2003;228:63-69.
ABSTRACT | FULL TEXT  

Neoadjuvant Chemotherapy, Locally Advanced Breast Cancer, and Quality of Life
McMasters and Hunt
JCO 1999;17:441-441.
FULL TEXT  

Locally Advanced Breast Cancer
Valero et al.
The Oncologist 1996;1:8-17.
ABSTRACT | FULL TEXT